The glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy, Ozempic) was found to demonstrate no increased risk of suicidal ideation in patients with obesity or type 2 diabetes, according to retrospective analyses of electronic health records examining these patient populations, published in Nature Medicine. Researchers’ analysis of 240,618 patients who were overweight/obese showed that those taking semaglutide had a significantly lower risk (0.11%) of suicidal ideation compared with those using non-GLP-1 anti-obesity medications (0.43%). In …
Read More![Studies Find No Increased Risk of Suicide With Semaglutide Studies Find No Increased Risk of Suicide With Semaglutide](https://www.jucm.com/wp-content/uploads/2024/01/Semaglutide-Weight-Loss-Overweight-Female-in-Doctors-Office-with-Young-Female-Provider-in-Whitecoat-Exam-Checkup-380x253-1.jpg)